Navigating HER2 Heterogeneity: Precision Pathways in Breast Cancer Treatment

A panelist discusses how differences in HER2-positive, HER2-low, and HER2-negative status impact clinical decision-making.

Now Viewing

EP: 1.Navigating HER2 Heterogeneity: Precision Pathways in Breast Cancer Treatment

EP: 2.Metastatic Breast Cancer Treatment Guidelines and the Nuances of HER2-Low Disease in Clinical Practice

EP: 3.Transforming Breast Cancer Treatment Through ADC-Targeting Mechanisms

EP: 4.How ADC Design Influences Efficacy and Safety

EP: 5.Beyond HER2: Expanding the Biomarker Testing Landscape in Metastatic Breast Cancer

EP: 6.Comparing Approved ADC Options in HER2-Negative and HER2-Low Breast Cancer

EP: 7.Key Considerations for Oncology Pharmacists When Selecting and Sequencing ADC Therapies

EP: 8.Emerging ADC Clinical Trial Evidence in Breast Cancer Treatment

EP: 9.Personalizing ADC Therapy in mBC Based on Patient Characteristics and Prior Therapies

EP: 10.Practical Insights for Pharmacists on ADC Administration, Patient Experience, and Supportive Care

EP: 11.Managing ADC Toxicities and Infusion Reactions With Supportive Care Strategies

EP: 12.Monitoring Strategies for Managing ADC Toxicities in mBC

EP: 13.Optimizing ADC Supportive Care Prescribing and AE Management With Institutional Workflows

EP: 14.Discussing ADC Risks, Benefits, and Regimens With Patients

EP: 15.Interdisciplinary Approaches to Breast Cancer Care and ADC Treatment Barriers Due to Social Determinants of Health

EP: 16.Concluding Remarks: Collaborative Expertise in an Era of Emerging Cancer Therapies

Related Videos

Related Content

Advertisement

March 4th 2024

Integration of DBS Shows Promise Identifying Dysfunctional Brain Circuits, Treating Brain Disorders

Gillian McGovern, Associate Editor

February 5th 2024

Study Results Highlight Importance of Overcoming Stigma When Addressing Brain Health

Gillian McGovern, Associate Editor

January 22nd 2024

Study Findings Suggest Liver Creates Palmitic Acid, Maintaining Brain Health

Gillian McGovern, Associate Editor

January 15th 2024

Individuals With Obesity More Likely to Have MGUS, A Multiple Myeloma Precursor

Gillian McGovern, Associate Editor

January 9th 2024

FDA Accepts sBLA for Tisotumab Vedotin-tftv for the Treatment of Recurrent, Metastatic Cervical Cancer

Gillian McGovern, Associate Editor

January 9th 2024

Study Data Show Telemedicine Endocrinology Care Not as Effective as In-Person Care

Erin Hunter, Associate Editor

Related Content

Advertisement

March 4th 2024

Integration of DBS Shows Promise Identifying Dysfunctional Brain Circuits, Treating Brain Disorders

Gillian McGovern, Associate Editor

February 5th 2024

Study Results Highlight Importance of Overcoming Stigma When Addressing Brain Health

Gillian McGovern, Associate Editor

January 22nd 2024

Study Findings Suggest Liver Creates Palmitic Acid, Maintaining Brain Health

Gillian McGovern, Associate Editor

January 15th 2024

Individuals With Obesity More Likely to Have MGUS, A Multiple Myeloma Precursor

Gillian McGovern, Associate Editor

January 9th 2024

FDA Accepts sBLA for Tisotumab Vedotin-tftv for the Treatment of Recurrent, Metastatic Cervical Cancer

Gillian McGovern, Associate Editor

January 9th 2024

Study Data Show Telemedicine Endocrinology Care Not as Effective as In-Person Care

Erin Hunter, Associate Editor